Successful review of HAMLET Pharma by the EU Horizon 2020 program
Hamlet Pharma has recently delivered its 18-month report to the European Union’s Horizon 2020 program. In their response, the EU states that the project has “fully achieved its objectives and milestones for the period” and “remains in line with the objectives”.The report summarizes the results in four parts. 1. The successful conclusion of the Phase I/II study. The report states that “the results demonstrated good safety and efficacy, which is very encouraging and supports the continued development of Alpha1H towards a Phase III trial”. 2. Transfer of the drug manufacturing